Effects of escin on indinavir crystallization time in the urine of patients with HIV-I infection: A multicenter, randomized, open-label, controlled, four-period crossover trial

Clinical Therapeutics

Volumn 26, Issue 12, 2004, Pages 2045-2055

  Grases, Felix ^a   Garca Gonzlez, Ramn ^b   Redondo, Enrique ^c   Costa Bauz, Antonia ^a   Simonet, Bartolom M ^a   Sartini, Raquel P ^a   Bassa, Antoni ^b   Gallegos, Carmen ^b   Payeras, Antoni ^b   Saro, Dulce ^b   Martinez, Ana Isabel ^b   Cifuentes, Carmen ^d   Homar, Francisco ^d   Murillo, Jos A ^c   Fernndez, Cristina ^c   Riera, Melchor ^e   Conte, Antonio ^e  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^b Hospital Joan March   (Spain)

^c Medical affairs Merck sharp and Dohme ltd   (Spain)

^d Hospital General de Mallorca   (Spain)

^e HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Clinical trial; Escin; HIV; Indinavir; Nephrolithiasis; Urine crystallization

Indexed keywords

ANTIRETROVIRUS AGENT; ESCIN; INDINAVIR; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CRYSTALLIZATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATURIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY COLIC; MALE; NEPHROLITHIASIS; RANDOMIZED CONTROLLED TRIAL; SEX ROLE; SIDE EFFECT; TREATMENT WITHDRAWAL; URINALYSIS; URINE PH; VIRUS LOAD;

EID: 20144371732     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2004.12.014     Document Type: Article

References (17)

1. Palella FJ Jr, Delaney KM, Moorman AC Outpatient Study Investigators Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection N Engl J Med 338 1998 853 860
2. Gulick RM, Mellors JW, and Havlir D Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy N Engl J Med 337 1997 734 739
3. Gulick RM, Mellors JW, and Havlir D Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-Week follow-up JAMA 280 1998 35 41
4. Hortin GL, King C, Miller KD, and Kopp JB Detection of indinavir crystals in urine: Dependence on method of analysis Arch Pathol Lab Med 124 2000 246 250
5. Dieleman JP, Salahuddin S, and Hsu YS Indinavir crystallization around the loop of Henle: Experimental evidence J Acquir Immune Defic Syndr 28 2001 9 13
6. Kopp JB, Miller KD, and Mican JA Crystalluria and urinary tract abnormalities associated with indinavir Ann Intern Med 127 1997 119 125
7. Gulick RM, Mellors JW, and Havlir D 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine Ann Intern Med 133 2000 35 39
8. Grases F, Costa-Bauz A, and Garcia-Gonzalez R Indinavir crystallization and urolithiasis Int Urol Nephrol 31 1999 23 29
9. Sirtori CR Aescin: Pharmacology, pharmacokinetics and therapeutic profile Pharmacol Res 44 2001 183 193
10. Frick RW Three treatments for chronic venous insufficiency: Escin, hydroxyethylrutoside, and Daflon Angiology 51 2000 197 205
11. [in German] Greeske K, and Pohlmann BK Horse chestnut seed extract--an effective therapy principle in general practice. Drug therapy of chronic venous insufficiency Fortschr Med 114 1996 196 200
12. Ottilinger B, and Greeske K Rational therapy of chronic venous insufficiency--changes and limits of the therapeutic use of horse-chestnut seeds extract BMC Cardiovasc Disord 1 2001 5
13. Grases F, Ramis M, Villacampa AI, and Costa-Bauz A Uric acid urolithiasis and crystallization inhibitors Urol Int 62 1999 201 204
14. Kunz K, Lorkowski G, and Petersen G Bioavailability of escin after administration of two oral formulations containing Aesculus extract Arzneimittelforschung 48 1998 822 825
15. Burger DM, de Graaf M, and Wuis EW Determination of indinavir, an HIV-protease inhibitor, in human plasma by reversed-phase high-performance liquid chromatography J Chromatogr B Biomed Sci Appl 703 1997 235 241
16. Li LY, Rodriguez-Hornedo N, Heimbach T, and Fleisher D In-vitro crystallization of indinavir in the presence of ritonavir and as a function of pH J Pharm Pharmacol 55 2003 707 711
17. Trinchieri A Epidemiology of urolithiasis Arch Ital Urol Androl 68 1996 203 249